DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported a loss of $26.8 million in its fourth quarter.

The Durham, North Carolina-based company said it had a loss of 13 cents per share.

The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 6 cents per share.

The drugmaker posted revenue of $131.5 million in the period.

For the year, the company reported that its loss narrowed to $88.9 million, or 43 cents per share. Revenue was reported as $450.7 million.

BioCryst expects full-year revenue in the range of $560 million to $575 million.

BioCryst shares have climbed 22% since the beginning of the year. The stock has increased 58% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX